Comparison of Pathologist and Artificial Intelligence-based Grading for Prediction of Metastatic Outcomes After Radical Prostatectomy.

Journal: European urology oncology
PMID:

Abstract

Gleason grade group (GG) is the most powerful prognostic variable in localized prostate cancer; however, interobserver variability remains a challenge. Artificial intelligence algorithms applied to histopathologic images standardize grading, but most have been tested only for agreement with pathologist GG, without assessment of performance with respect to oncologic outcomes. We compared deep learning-based and pathologist-based GGs for an association with metastatic outcome in three surgical cohorts comprising 777 unique patients. A digitized whole slide image of the representative hematoxylin and eosin-stained slide of the dominant tumor nodule was assigned a GG by an artificial intelligence-based grading algorithm and was compared with the GG assigned by a contemporary pathologist or the original pathologist-assigned GG for the entire prostatectomy. Harrell's C-indices based on Cox models for time to metastasis were compared. In a combined analysis of all cohorts, the C-index for the artificial intelligence-assigned GG was 0.77 (95% confidence interval [CI]: 0.73-0.81), compared with 0.77 (95% CI: 0.73-0.81) for the pathologist-assigned GG. By comparison, the original pathologist-assigned GG for the entire case had a C-index of 0.78 (95% CI: 0.73-0.82). PATIENT SUMMARY: Artificial intelligence-enabled prostate cancer grading on a single slide was comparable with pathologist grading for predicting metastatic outcome in men treated by radical prostatectomy, enabling equal access to expert grading in lower resource settings.

Authors

  • Lia D Oliveira
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Jiayun Lu
    Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Eric Erak
    Department of Pathology, Johns Hopkins University School of Medicine.
  • Adrianna A Mendes
    Department of Pathology, Johns Hopkins University School of Medicine.
  • Oluwademilade Dairo
    Department of Pathology, Johns Hopkins University School of Medicine.
  • Onur Ertunc
    Department of Pathology, Suleyman Demirel University, Turkey.
  • İbrahim Kulaç
    Department of Pathology, Koç University Hospital, İstanbul, Turkey.
  • Javier A Baena-Del Valle
    Fundacion Santa Fe de Bogota University Hospital, Columbia.
  • Tracy Jones
    Department of Pathology, Johns Hopkins University School of Medicine.
  • Jessica L Hicks
    Department of Pathology, Johns Hopkins University School of Medicine.
  • Stephanie Glavaris
    Department of Pathology, Johns Hopkins University School of Medicine.
  • Gunes Guner
    Hacettepe University, Turkey.
  • Igor D Vidal
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Bruce J Trock
    Division of Epidemiology, Brady Urological Institute, Johns Hopkins Medical Institution, Baltimore, MD, USA.
  • Uttara Joshi
    AIRAMATRIX PVT. LTD., Mumbai, India.
  • Chaith Kondragunta
    AIRA Matrix Private Limited, India.
  • Saikiran Bonthu
  • Corinne Joshu
    Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Nitin Singhal
  • Angelo M De Marzo
    Department of Pathology, Johns Hopkins University School of Medicine; Department of Oncology, Johns Hopkins University School of Medicine; Department of Urology, Johns Hopkins University School of Medicine.
  • Tamara L Lotan
    Department of Pathology, Johns Hopkins University School of Medicine; Department of Oncology, Johns Hopkins University School of Medicine; Department of Urology, Johns Hopkins University School of Medicine. Electronic address: tlotan1@jhmi.edu.